title: Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study.
abstract: OBJECTIVE
  From December 1983 through February 1992, a prospective study designed to determine the clinical course of patients with ovarian tumors of low malignant potential (LMP) was conducted by the Gynecologic Oncology Group (GOG).
  
  
  METHODS
  This protocol was developed to evaluate the following (1) the biologic behavior of ovarian LMP tumors, (2) the effectiveness of melphalan chemotherapy in patients with clinically detectable residual disease after surgical staging and in patients whose tumors progress or recur after surgical therapy, and (3) the response rate to cisplatin in those who failed to respond to melphalan therapy. The study group consisted of 146 assessable patients with stage I serous LMP tumors. All of these women had the affected ovary (or ovaries) removed, and a complete staging operation was performed in each case. While 123 patients had a total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO), 21 retained the uterus and one normal-appearing ovary and fallopian tube. No adjuvant chemotherapy or radiation therapy was administered to any patients in the stage I study group.
  
  
  RESULTS
  The median follow-up time was 42.4 months (range, 1.6 to 108). Thus far, no patient with a stage I ovarian serous LMP tumor has developed recurrent disease.
  
  
  CONCLUSIONS
  Stage I ovarian serous LMP tumors rarely, if ever, recur. Limited resection, after meticulous surgical exploration, is adequate therapy for women of reproductive age.
authors.affiliation: Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Barnhill
authors.forename: R J
authors.initials: RJ
authors.lastname: Kurman
authors.forename: M F
authors.initials: MF
authors.lastname: Brady
authors.forename: G A
authors.initials: GA
authors.lastname: Omura
authors.forename: E
authors.initials: E
authors.lastname: Yordan
authors.forename: F T
authors.initials: FT
authors.lastname: Given
authors.forename: P R
authors.initials: PR
authors.lastname: Kucera
authors.forename: L D
authors.initials: LD
authors.lastname: Roman
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D011446:Prospective Studies; D014481:United States
chemical_list: D002945:Cisplatin; D008558:Melphalan